US Patent 8,846,650: Claim Scope, Expiration, Orange Book Status, and Ciprodex Patent Landscape

US Patent 8,846,650 covers a treatment method for otitis media using an aqueous ciprofloxacin-dexamethasone suspension administered through an ear canal with an open tympanic membrane. The patent does not claim ciprofloxacin-dexamethasone as a composition in the abstract. Its independent claim requires a specific diagnosis, anatomical condition, route of administration, formulation profile, and pH range.

The commercially relevant embodiment corresponds closely to Ciprodex, an otic suspension containing 0.3% ciprofloxacin and 0.1% dexamethasone. The patent was issued on September 30, 2014. Its term is tied to the earlier nonprovisional family filing rather than the issue date and reached its ordinary statutory endpoint in 2024, subject to any patent-term adjustment shown in the USPTO record. The patent therefore presents limited current blocking risk for new U.S. generic launches, although historical Paragraph IV litigation and infringement exposure were material before expiration.

What does US Patent 8,846,650 cover?

The patent covers a method of treating middle-ear infection by placing a specified ciprofloxacin-dexamethasone suspension in the ear canal of a patient diagnosed with otitis media who has an open tympanic membrane.

Claim 1 requires all of the following elements:

Element	Requirement
Patient	Human patient
Disease	Otitis media, characterized as a middle-ear infection
Diagnosis	Patient must be diagnosed with otitis media
Anatomy	At least one ear has an open tympanic membrane
Route	Topical application into the ear canal
Dosage form	Aqueous suspension
Antibiotic	Ciprofloxacin at 0.1% to 0.4% by weight
Corticosteroid	Dexamethasone at 0.01% to 0.5% by weight
Tonicity	NaCl as the tonicity agent, producing approximately 250 to 350 mOsm osmolality
Polymer	0.1% to 0.5% nonionic polymer
Surfactant	0.01% to 0.2% nonionic surfactant
Buffer	A buffer
pH	Approximately 3 to 5

A product or treatment protocol must satisfy the full combination. A formulation containing ciprofloxacin and dexamethasone but lacking the required tonicity, polymer, surfactant, or pH characteristics would not literally meet claim 1.

The patent is therefore a combination method patent. It is narrower than a broad claim to the active ingredients or to any ciprofloxacin-dexamethasone otic formulation.

How do claims 2 through 10 narrow the patent?

Claims 2 through 10 add formulation, dosage, disease, delivery, particle-size, or labeling limitations.

Claim	Additional limitation	Commercial significance
2	Dexamethasone alcohol and ciprofloxacin hydrochloride monohydrate	Targets the active ingredients used in the commercial product
3	0.1% dexamethasone and 0.3% ciprofloxacin	Matches the principal Ciprodex strength
4	Three or four drops, twice daily; each drop 30-35 microliters	Targets the labeled dosing regimen
5	Specific formulation including HEC, tyloxapol, acetate buffer, benzalkonium chloride, edetate disodium, and boric acid	Closely defines the commercial formulation
6	Pumping the tragus to force the suspension through the open tympanic membrane	Covers a specified administration technique
7	Dexamethasone average particle size below 3 micrometers	Adds a particle-engineering limitation
8	Acute otitis media	Narrows the disease indication
9	Chronic suppurative otitis media	Narrows the disease indication
10	Packaging with directions stating use in patients with an open tympanic membrane	Creates a label and induced-infringement focus

Claims 3, 4, and 5 are the most commercially important because they map onto the principal concentration, dosing schedule, and excipient profile of Ciprodex. Claim 10 is important in generic litigation because a generic label can create infringement exposure even when the manufacturer does not directly perform the treatment method.

What formulation does claim 5 protect?

Claim 5 is directed to a specific suspension containing:

0.1% dexamethasone alcohol;
0.35% ciprofloxacin hydrochloride monohydrate;
sodium chloride sufficient to produce 250 to 350 mOsm;
0.2% hydroxyethyl cellulose;
0.05% tyloxapol;
sodium acetate and acetic acid buffer;
0.01% benzalkonium chloride;
0.01% edetate disodium;
0.6% boric acid; and
a pH of approximately 4.5.

The phrase "consists essentially of" is significant. It generally permits additional components that do not materially alter the basic and novel characteristics of the claimed formulation. It is narrower than "comprising" but broader than "consisting of."

A competing product could attempt to avoid claim 5 by changing one or more ingredients or concentrations. That strategy would not automatically avoid claim 1, however. Claim 1 uses broader ranges and functional categories, including a nonionic polymer, a nonionic surfactant, sodium chloride-based tonicity, and pH of approximately 3 to 5.

Does the patent claim Ciprodex itself?

No. The patent claims a method that can be practiced using a Ciprodex-type formulation.

Ciprodex contains ciprofloxacin hydrochloride and dexamethasone, generally at 0.3% and 0.1%, respectively. Claim 3 expressly covers those active concentrations. Claim 5 covers a more detailed formulation profile. The patent does not create a composition-of-matter monopoly over ciprofloxacin, dexamethasone, or every otic suspension containing both ingredients.

This distinction affects generic design-around strategies:

A generic manufacturer could use different excipients.
It could use a different pH or tonicity profile.
It could use a different polymer or surfactant.
It could omit or alter the open-tympanic-membrane indication.
It could challenge the patent rather than redesign the formulation.

Each strategy must be evaluated against the broader limitations of claim 1 and the doctrine of equivalents.

When did US Patent 8,846,650 expire?

US Patent 8,846,650 was issued on September 30, 2014. Patent term is generally calculated from the earliest effective U.S. nonprovisional filing date for the relevant family, not from the date of issuance. The family’s ordinary 20-year term reached its statutory endpoint in 2024, subject to any patent-term adjustment reflected in the USPTO file history. The patent should therefore be treated as expired for ordinary present-day U.S. freedom-to-operate analysis unless the USPTO record shows an unusual term adjustment or other operative status.

The patent’s expiration is distinct from FDA regulatory exclusivity. FDA approval of Ciprodex occurred in 2003, and regulatory exclusivity does not extend the patent term.

Exclusivity timeline

Event	Date or period
Ciprodex FDA approval	2003
US Patent 8,846,650 issue	September 30, 2014
Ordinary 20-year patent endpoint	2024, based on the relevant family term
Post-expiration generic risk	Primarily regulatory, formulation, manufacturing, and remaining patent-family issues

A definitive patent expiration calculation must use the USPTO patent-term data, including any patent-term adjustment and terminal disclaimer. The issue date alone does not establish the expiration date.

What was the Orange Book status of the patent?

The Orange Book is the FDA’s authoritative source for patents listed against approved drug products. For a drug such as Ciprodex, listed patents can include formulation, method-of-use, or other patents that an ANDA applicant must address under Hatch-Waxman.

US Patent 8,846,650 is relevant to Ciprodex-style products because its claims track the product’s formulation and labeled use in patients with an open tympanic membrane. A patent listing does not establish validity or enforceability. It gives an ANDA applicant a regulatory patent-certification obligation.

The relevant certification pathways are:

Paragraph I: no patent information is listed;
Paragraph II: the patent has expired;
Paragraph III: the applicant will wait until patent expiration;
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

After expiration, the practical Orange Book significance of the patent is limited. A live listing can remain relevant to historical approvals or administrative records, but it should not be treated as an operative barrier without confirming the FDA listing and USPTO status.

What Paragraph IV challenges affected ciprofloxacin-dexamethasone otic products?

A generic applicant seeking approval before patent expiration would typically have used a Paragraph IV certification against any listed patent believed to be invalid, unenforceable, or not infringed. The certification would have required notice to the patent holder and NDA holder and could have triggered a 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the statutory conditions.

For US Patent 8,846,650, likely Paragraph IV arguments would have focused on:

Noninfringement

A generic applicant could argue that its formulation does not contain:

NaCl as the relevant tonicity agent;
the required osmolality;
a nonionic polymer within the claimed range;
a nonionic surfactant within the claimed range;
a pH between approximately 3 and 5; or
the specific open-tympanic-membrane labeling required by claims 1 and 10.

Invalidity

Potential invalidity theories would include:

anticipation by an earlier ciprofloxacin-dexamethasone otic formulation;
obviousness based on known otic antibiotic-steroid combinations;
lack of written description for the claimed ranges or formulation combinations;
lack of enablement for the full scope of the method;
indefiniteness involving terms such as "about," "open tympanic membrane," or "consists essentially of."

The patent’s strongest defense would likely be the combination of formulation limitations with a specific clinical condition and administration route. Its vulnerability would likely center on the predictability of combining known excipients and administering known ciprofloxacin-dexamethasone products to patients with tympanostomy tubes or perforated tympanic membranes.

What litigation risk did the patent create for generic manufacturers?

The main risk was induced infringement under 35 U.S.C. § 271(b). Claims 1 and 10 are method claims, and a generic manufacturer could be accused of inducing infringement if its labeling encouraged physicians or patients to use the product in the claimed manner.

The risk analysis depended on the proposed generic label:

Generic label position	Risk profile
Includes otitis media with open tympanic membrane	High method-claim exposure
Includes ciprofloxacin-dexamethasone dosing matching claims 3 and 4	Increased exposure
Omits the open-tympanic-membrane indication	Reduces literal inducement risk
Uses a materially different formulation	Reduces formulation overlap
Markets only for an unclaimed indication	May support a section viii carve-out, depending on FDA requirements
Launches after patent expiration	Eliminates ordinary infringement exposure from this patent

A skinny-label strategy would have been difficult if the open-tympanic-membrane indication was central to the approved use and could not be removed without materially altering the product’s regulatory labeling.

No conclusion about a particular settlement agreement, consent judgment, or active case should be drawn from the patent number alone. Litigation history must be checked against the district court docket, Federal Circuit decisions, FDA patent records, and the patent’s prosecution file.

Which companies challenged Ciprodex exclusivity?

Ciprodex was developed and commercialized by Alcon, with later ownership and commercialization associated with Novartis and subsequently other ophthalmic and pharmaceutical portfolios. Generic competition has involved manufacturers seeking approval for ciprofloxacin hydrochloride and dexamethasone otic suspension products.

The competitive field includes:

branded Ciprodex;
authorized or licensed generic versions;
ANDA products using the same active ingredients;
products with alternative excipient systems;
separate antibiotic or steroid otic products that do not replicate the combination.

The relevant challenger is not determined solely by whether a company markets ciprofloxacin-dexamethasone. The key questions are whether the product was approved before the patent endpoint, whether it filed a Paragraph IV certification, and whether its label and formulation practiced the asserted claims.

How strong is the patent estate around Ciprodex?

The estate was stronger before 2024 than it is today.

Strengths

Claim 1 combines multiple formulation parameters with a defined clinical setting.
Claims 3 through 5 align closely with the commercial product.
Claim 10 creates label-based inducement exposure.
The open-tympanic-membrane limitation addresses a clinically specific use rather than a generalized topical ear treatment.
The claimed pH and excipient ranges could make literal design-around more difficult for products closely copying Ciprodex.

Weaknesses

The patent is a method patent, not a composition-of-matter patent.
The active ingredients were known before the patent family.
The claimed formulation includes conventional pharmaceutical excipients.
Several terms use approximate ranges and functional language.
The patent’s ordinary term ended in 2024.
A generic manufacturer can potentially alter the label, formulation, or both.

The patent was therefore commercially meaningful as a pre-expiration Hatch-Waxman asset but is not a durable barrier to current U.S. generic competition.

What manufacturing and intellectual-property barriers remain?

Patent expiration does not eliminate all market-entry barriers. A generic manufacturer still must:

Demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the otic product.
Control particle size and suspension uniformity.
Maintain physical stability of ciprofloxacin and dexamethasone across the product shelf life.
Reproduce or replace the viscosity, wetting, and resuspendability functions supplied by hydroxyethyl cellulose and tyloxapol.
Control preservative performance from benzalkonium chloride.
Manufacture the product under current good manufacturing practice requirements.
Address device, dropper, container-closure, and fill-volume requirements.
Avoid any still-active continuation, divisional, or related patent not analyzed solely from US Patent 8,846,650.

The manufacturing barrier is moderate rather than fundamental. The formulation uses established excipients and conventional dosage-form technology, but suspension uniformity, particle-size control, preservative compatibility, and container performance can affect approval and commercial reliability.

How does US Patent 8,846,650 compare with a broad Ciprodex composition patent?

Issue	US Patent 8,846,650	Broad composition patent
Claim type	Treatment method	Composition
Patient condition required	Yes	Usually no
Open tympanic membrane required	Yes	Usually no
Formulation limitations	Extensive	May be broad or narrow
Label-based infringement	Important	Less dependent on label
Design-around potential	Relatively high	Often lower if composition scope is broad
Post-expiration value	Minimal	Minimal after expiration
Main Hatch-Waxman issue	Induced method infringement	Direct or formulation infringement

The patent’s value came from the interaction between the commercial formulation and the approved indication. A competitor could avoid some risk by changing the formulation, the label, or both.

What is the current generic launch risk?

For the United States, US Patent 8,846,650 should not be treated as an active barrier after its 2024 patent-term endpoint. Current launch risk is more likely to depend on:

FDA approval timing;
remaining Orange Book-listed patents;
related continuation patents;
formulation equivalence;
manufacturing scale-up;
product quality;
reimbursement and contracting;
branded pricing;
supply reliability; and
state substitution rules.

A generic product launched before the patent endpoint would have faced meaningful Paragraph IV and induced-infringement risk. A product launched after expiration faces substantially lower patent risk from this patent, provided no related unexpired patent covers the same formulation, use, or manufacturing process.

Key Takeaways

US Patent 8,846,650 is a method patent covering treatment of otitis media in a patient with an open tympanic membrane.
Claim 1 requires a specific aqueous suspension containing ciprofloxacin, dexamethasone, sodium chloride-based tonicity, a nonionic polymer, a nonionic surfactant, a buffer, and pH of approximately 3 to 5.
Claims 3, 4, and 5 closely track the commercial Ciprodex concentration, dosing schedule, and excipient system.
Claim 10 creates potential induced-infringement exposure through labeling that directs use in patients with an open tympanic membrane.
The patent is not a broad composition-of-matter patent for ciprofloxacin, dexamethasone, or every combination product.
Its ordinary U.S. patent term ended in 2024, subject to the USPTO-recorded patent-term adjustment.
Historical Paragraph IV exposure was material, but the patent presents limited current blocking risk after expiration.
Remaining generic-entry risks are more likely to involve related patents, FDA approval, manufacturing controls, formulation performance, and commercial execution.

FAQs

Does US Patent 8,846,650 cover ciprofloxacin-dexamethasone eye drops?

No. The claims require treatment of otitis media through topical application into the ear canal. An ophthalmic product used only in the eye would not satisfy the claimed route or disease limitations.

Does a perforated eardrum satisfy the open tympanic membrane limitation?

Generally, a perforation can represent an open tympanic membrane, but infringement depends on the claim construction applied to the specific clinical facts and product labeling.

Can a generic avoid the patent by using ciprofloxacin base instead of ciprofloxacin hydrochloride monohydrate?

Potentially, particularly against claim 2 and claim 5. That change would not automatically avoid claim 1, which recites ciprofloxacin more broadly.

Does a pH of 5.2 avoid the patent?

It would likely avoid the literal pH limitation of claim 1, which requires a pH from approximately 3 to 5. The effect of the word "about" and any doctrine-of-equivalents argument would depend on the technical record and claim construction.

Does patent expiration eliminate FDA exclusivity?

No. Patent expiration and FDA regulatory exclusivity are separate rights. Patent expiration removes the patent barrier, but FDA approval, exclusivity periods, Orange Book requirements, and applicable ANDA rules still govern generic entry.

References

U.S. Food and Drug Administration. (2003). Ciprodex prescribing information: Ciprofloxacin hydrochloride and dexamethasone otic suspension. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,846,650: Treatment of otitis media. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term information. U.S. Department of Commerce.
United States Code, 21 U.S.C. § 355. (2024). New drug applications and abbreviated applications.
United States Code, 35 U.S.C. §§ 271, 281, 282. (2024). Patent infringement, remedies, and defenses.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1429780	⤷ Start Trial	CA 2012 00045	Denmark	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	13C0012	France	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	SPC/GB12/058	United Kingdom	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	122012000070	Germany	⤷ Start Trial
European Patent Office	1429780	⤷ Start Trial	132013902137451	Italy	⤷ Start Trial
Austria	313328	⤷ Start Trial
Australia	2002333671	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,846,650

Summary for Patent: 8,846,650